Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 548-559

  De Jonge, Hylke ^a   Vanhove, Thomas ^a   De Loor, Henriëtte ^b   Verbeke, Kristin ^a   Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cyclosporine; CYP3A4; CYP3A5; CYP3A5 1; kidney transplantation; tacrolimus

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MIDAZOLAM; TACROLIMUS; CALCINEURIN INHIBITOR; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG WITHDRAWAL; ELIMINATION RATE CONSTANT; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; BLOOD; DOSE RESPONSE; GENETICS; GRAFT REJECTION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED;

AREA UNDER CURVE; CALCINEURIN INHIBITORS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEMATOCRIT; HUMANS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; TACROLIMUS;

EID: 84940033403     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12703     Document Type: Article

References (39)

1. Schiff J, Cole E, Cantarovich M,. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2: 374-84.
2. De Jonge H, Naesens M, Kuypers DRJ,. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416-35.
3. Meier-Kriesche HU, Li S, Gruessner RWG, Fung JJ, Bustami RT, Barr ML, Leichtman AB,. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-31.
4. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ,. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264: 10388-95.
5. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE,. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-47.
6. Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, Wojnowski L,. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374-81.
7. Hebert MF,. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-14.
8. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T,. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80.
9. Cummins CL, Jacobsen W, Christians U, Benet LZ,. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 2004; 308: 143-55.
10. Benet LZ, Cummins CL, Wu CY,. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004; 277: 3-9.
11. Wu C-Y, Benet LZ,. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
12. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y,. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004; 43: 741-62.
13. Kuypers DRJ, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y,. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711-25.
14. Hesselink DA, van Schaik RHN, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DRJ, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T,. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339-48.
15. Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M,. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 2008; 85: 1139-45.
16. Macphee IAM, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW,. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9.
17. Hesselink DA, Van Schaik RHN, Van Der Heiden IP, Van Der Werf M, Smak Gregoor PJH, Lindemans J, Weimar W, Van Gelder T,. Genetic polymorphisms of the CεP3A4, CεP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
18. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD,. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994; 271: 557-66.
19. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR,. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
20. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD,. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133-43.
21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ,. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-71.
22. De Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DRJ,. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics 2013; 14: 1467-80.
23. De Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR,. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 2012; 92: 366-75.
24. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F,. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
25. Miller SA, Dykes DD, Polesky HF,. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
26. De Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR,. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1′-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomed Chromatogr 2011; 25: 1091-8
27. Napoli KL, Hammett-Stabler C, Taylor PJ, Lowe W, Franklin ME, Morris MR, Cooper DP,. Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. Clin Biochem 2010; 43: 910-20.
28. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T,. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-30.
29. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-53.
30. Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, Kaneko S, Kobayashi K-I, Miyamoto K-I,. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002; 74: 1419-24.
31. Van Duijnhoven EM, Boots JMM, Christiaans MHL, Stolk LML, Undre NA, van Hooff JP,. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16: 721-5.
32. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E,. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409-14.
33. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RHN,. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-83.
34. De Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DRJ,. The CYP3A4∗22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J 2015; 15: 144-52.
35. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C,. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther United States; 2000; 68: 356-66.
36. Benet LZ,. The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 2009; 6: 1631-43.
37. Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, Edefonti A,. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 2007; 11: 296-300.
38. De Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DRJ,. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clin Pharmacol Ther 2011; 90: 414-22.
39. Amundsen R, Åsberg A, Ohm IK, Christensen H,. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos 2012; 40: 655-61.